Nadia Litterman, PhD is Collaborations Director at Collaborative Drug Discovery (CDD), where she aims to identify and develop collaborations for drug discovery using CDD’s innovative informatics technologies. She has a long-standing interest in finding therapeutics for neuronal disorders and rare diseases, with more than 10 years of broad research experience in the areas of chemistry, cell biology, and neuroscience.
During postdoctoral research in the laboratory of Dr. Lee Rubin at Harvard University, she utilized stem cell models of the rare, genetic, early onset motor neuron disorder Spinal Muscular Atrophy (SMA) to search for novel therapeutic strategies. She identified an opportunity for drug repurposing of an anti-cancer compound for SMA and found that this approach may be broadened for a second disease of motor neurons, Amyotrophic Lateral Sclerosis (ALS).
As a National Science Foundation graduate fellow in the Pathology Department at Harvard Medical School, she led an investigation to explore biochemical processes that control protein trafficking in neurons.
Her undergraduate research in the Chemistry department at Princeton University focused on free radical toxicity as it relates to protein misfolding and neurodegeneration.